Article Text

Download PDFPDF
Telomerase antisense inhibition for the proliferation of endometrial cancer in vitro and in vivo
  1. X. J. Chen*,
  2. W. Zheng*,
  3. L. L. Chen*,
  4. Z. B. Chen and
  5. S. Q. Wang
  1. * Second Hospital of Zhejiang University School of Medicine, Hangzhou, China
  2. Beijing Institute of Radiation Medicine, Beijing, China
  1. Address correspondence and reprint requests to: Wei Zheng, MD, PhD, Second Hospital of Zhejiang University School of medicine, 88 Jiefang Road, Hangzhou 310009, China. Email: startchen{at}


The objective of this study was to investigate the antitumor effect of antisense telomerase oligodeoxynucleotides to endometrial cancer cells in vitro and in vivo. Antisense oligodeoxynucleotides (ODNs) against the human telomerase transcripatse (hTERT) synthesized to serve as telomerase inhibitors. Reverse transcription–polymerase chain reaction and 3-[4,5-dimethylthiazol-2yl]-2,5-diphenyltetrazolium bromide (MTT) assay were used to test the expression of hTERT messengerRNA (mRNA) and inhibition of cell proliferation in vitro. In vivo, antitumor effects of ODNs or combined with cisplatin were evaluated in endometrial cancer xenograft. Telomerase activity was tested by telomeric repeat amplification protocol. Antisense ODNs could inhibit proliferation of human endometrial cancer cells (HEC-1-A) in vitro, and downregulate the expression hTRET mRNA in a dose- and period-dependent manner. The tumor growth inhibitory rate of low- and high-dose ODNs were 34.20% and 89.21%, and combined group was 75.30%. Telomerase activity was downregulated to 87.32% compared to the control in the ODNs-treated xenograft tumors. Antisense oligonucleotides of hTERT effectively inhibit the growth of endometrial cancer cell line. Telomerase inhibitor might be a new strategy for chemotherapy or chemoprevention in endometrial cancer.

  • antisense
  • cisplatin
  • endometrial neoplasms
  • oligodeoxynucleotide
  • telomerase
  • transplantation

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.